Federal Biologics and Biosimilars Procurement Fraud Defense Lawyer - 42 U.S.C. § 262 and 18 U.S.C. § 1347
Federal investigations involving biologics and biosimilars often focus on allegations that healthcare executives, distributors, procurement officers, or pharmaceutical companies knowingly sourced, marketed, or distributed unapproved, counterfeit, diverted, or gray-market products.
These cases frequently involve allegations under 42 U.S.C. § 262, which governs biologics and biosimilars, as well as healthcare fraud charges under 18 U.S.C. § 1347 and related federal fraud statutes.
As the market for specialty biologics continues to expand, federal agencies have increased scrutiny of distribution chains, reimbursement claims, import practices, and product authentication procedures.
What may begin as an FDA regulatory inquiry can quickly develop into a criminal investigation involving the Department of Justice, the FBI, the Department of Health and Human Services Office of Inspector General (HHS OIG), and other federal enforcement agencies.
What are Biologics and Biosimilars?
Biologics are complex medical products derived from living organisms. They are commonly used to treat cancer, autoimmune disorders, rare diseases, and other medical conditions.
Biosimilars are products approved under 42 U.S.C. § 262(k) that are highly similar to an already licensed biological product.
What is Biologics and Biosimilars Procurement Fraud?
Federal procurement fraud allegations typically arise when prosecutors claim that an individual or company knowingly participated in conduct involving:
- Counterfeit biologic medications
- Unapproved biosimilars
- Foreign-sourced products not authorized for U.S. distribution
- Diverted pharmaceuticals sold outside approved channels
- Misrepresentations regarding product origin or regulatory status
- False reimbursement submissions to Medicare, Medicaid, or private insurers
- Altered documentation related to drug sourcing or chain of custody
These investigations often involve millions of dollars in product purchases and reimbursement claims, making them attractive targets for federal prosecutors.
Why Are Federal Authorities Focusing on Biosimilar Distribution Networks?
Biologics are among the most expensive pharmaceutical products in the healthcare market. Because reimbursement rates can be substantial, investigators closely examine supply chains for evidence of fraud.
Federal authorities have expressed particular concern regarding:
- Counterfeit products entering legitimate distribution channels
- Foreign biosimilars that have not received FDA approval
- Product diversion schemes
- Mislabeling of biological products
- False certifications provided to healthcare systems
- Inflated reimbursement requests
- Procurement arrangements involving concealed intermediaries
In many cases, federal investigators focus on executives rather than lower-level employees. Prosecutors often seek evidence that decision-makers knew products were sourced outside approved channels but approved purchases anyway.
What Federal Laws Commonly Apply?
Federal biologics procurement investigations rarely rely on a single statute. When it comes to biologics and biosimilars fraud, we most often see the base charges to be:
- 42 U.S.C. § 262: Regulation of Biological Products
- 18 U.S.C. § 1347: Healthcare Fraud
But prosecutors frequently combine several criminal allegations into one case.
Related federal investigations often overlap with allegations discussed in cases involving mail fraud, internet fraud, forgery of corporate records, and destruction of corporate audit records.
Common federal statutes include:
- 18 U.S.C. § 1341: Mail Fraud
- 18 U.S.C. § 1343: Wire Fraud
- 18 U.S.C. § 371: Conspiracy
- 18 U.S.C. § 1001: False Statements
- 21 U.S.C. §§ 331 and 333: Federal Food, Drug, and Cosmetic Act violations
What Conduct Triggers Federal Criminal Investigations?
Not every regulatory violation results in criminal prosecution. Federal authorities may be alerted to alleged criminal behavior in a variety of ways.
Often, it is through routine compliance and reporting that discrepancies or suspicious data are identified. Whistleblowers can also trigger these investigations.
Criminal investigations generally focus on allegations involving intent, concealment, or deliberate deception. Examples include:
- Purchasing biosimilars from unauthorized foreign suppliers
- Using altered product pedigree documentation
- Concealing the origin of imported biologics
- Submitting reimbursement claims for products that differ from those actually administered
- Creating false certifications regarding FDA approval status
- Paying intermediaries to obscure sourcing activities
- Using shell companies to purchase restricted pharmaceutical products
- Falsifying inventory records during an FDA inspection
Federal investigators frequently review years of procurement records, contracts, emails, text messages, reimbursement submissions, and communications with distributors. These charges don't arise from mere suspicion or minimal evidence.
Who Becomes a Target in These Cases?
Companies working in biologics and biosimilars are large and complex; there are no mom-and-pop players in this industry.
This means that numerous people within the organizations can become targets of a federal investigation.
Many people assume that only pharmaceutical companies, as a whole, face exposure. In reality, federal prosecutors often focus on individuals. Potential targets include:
- Chief executive officers
- Chief financial officers
- Compliance officers
- Procurement executives
- Pharmaceutical wholesalers
- Distribution company owners
- Hospital purchasing directors
- Healthcare system administrators
- Third-party consultants
- Medical practice owners
The government may attempt to establish criminal intent by relying on internal communications, board meeting discussions, audit findings, or warnings allegedly received from vendors or regulators. The people whose names appear consistently in these documents are likely to be targeted.
How Do Federal Investigators Build Procurement Fraud Cases?
Federal agencies frequently spend months or years gathering evidence before any public charges are filed. Investigative techniques often include:
- Grand jury subpoenas
- Search warrants
- Confidential informants
- Whistleblower complaints
- FDA inspections
- HHS-OIG audits
- Financial record reviews
- Email and electronic communications analysis
Whistleblower allegations are particularly common in pharmaceutical procurement investigations.
A former employee may claim management knowingly purchased unapproved biosimilars or ignored warnings regarding counterfeit products.
Investigators then attempt to corroborate those allegations using procurement records, reimbursement data, and internal company communications.
Related Federal Laws
42 U.S.C. § 262 – Regulation of Biological Products
This law oversees the approval, licensing, manufacturing, and distribution of biologics and biosimilars in the U.S. Federal investigations often check if products are properly licensed, approved, and marketed according to FDA standards.
18 U.S.C. § 1347 – Health Care Fraud
Federal healthcare fraud prohibits knowingly executing a scheme to defraud a healthcare benefit program. Prosecutors often use this statute when alleging that providers or distributors submitted reimbursement claims for counterfeit, diverted, unapproved, or improperly sourced biologic products.
21 U.S.C. §§ 331 and 333 – Federal Food, Drug, and Cosmetic Act Violations
These regulations ban the shipment of adulterated, misbranded, counterfeit, or unapproved drugs across state lines. Violations related to biologics and biosimilars can lead to civil penalties and criminal charges.
18 U.S.C. § 1001 – False Statements to the Federal Government
Federal authorities often charge individuals with false statements when accusing executives, distributors, or healthcare organizations of deliberately providing incorrect information during inspections, audits, or investigations by agencies such as the FDA, HHS-OIG, or CMS.
18 U.S.C. § 371 – Conspiracy
Conspiracy charges are filed when prosecutors claim that two or more people conspired to commit a federal crime. In biologics procurement fraud cases, these conspiracy allegations are frequently paired with charges of healthcare fraud, wire fraud, false statements, and violations of the Food, Drug, and Cosmetic Act.
Why These Related Laws Matter
Federal biologics and biosimilars procurement investigations often involve multiple statutes. What starts as a regulatory review under 42 U.S.C. § 262 can quickly escalate to allegations of healthcare fraud, conspiracy, false statements, FDA violations, and other federal crimes.
Because these investigations often involve parallel criminal, civil, and administrative proceedings, early intervention by experienced federal defense counsel is essential to protect executives, healthcare providers, pharmaceutical companies, and their businesses.
Frequently Asked Questions (FAQs)
Can a company be criminally prosecuted for purchasing unapproved biologics?
Yes. Federal prosecutors can initiate criminal charges if they suspect a company knowingly bought, distributed, or billed for unapproved, counterfeit, diverted, or improperly imported biologics. The main concern in many cases is whether executives or employees were aware that the products were unauthorized or deliberately ignored warning signs.
Who can be targeted in a federal biologics fraud investigation?
Federal investigations typically target both individuals and companies. Possible targets encompass chief executive officers, compliance officers, procurement executives, pharmaceutical wholesalers, healthcare administrators, distribution company owners, hospital purchasing directors, and medical practice owners engaged in product sourcing or reimbursement activities.
How do federal biologics procurement fraud investigations usually begin?
Investigations often start with whistleblower complaints, FDA inspections, reimbursement audits, suspicious billing patterns, internal compliance reviews, or reports from distributors and healthcare providers. Federal agencies might also launch investigations upon discovering discrepancies related to product sourcing, chain-of-custody records, or reimbursement submissions.
What must prosecutors prove in a biologics procurement fraud case?
Federal prosecutors generally need to show that a defendant knowingly and intentionally committed fraudulent acts. Simply breaking a regulatory rule usually isn't enough. Instead, the government usually aims to prove that the defendant deliberately misrepresented the product's origin, hid sourcing details, made false claims, or intended to deceive regulators or healthcare programs.
What should I do if federal agents or FDA investigators contact me?
It is advisable to consult with an experienced federal criminal defense attorney before engaging in interviews, providing documents, or replying to investigative inquiries. Having legal support early on can safeguard your rights, help preserve key evidence, coordinate your responses with investigators, and possibly affect the decision to file charges.
What Are Common Defense Strategies?
Federal prosecutors must prove more than the existence of a regulatory problem to cross the threshold into criminal territory. They must establish that a defendant knowingly and intentionally engaged in criminal conduct.
Defense strategies often focus on:
- Lack of criminal intent
- Good-faith reliance on supplier representations
- Legitimate disputes regarding product classification
- Inadequate proof of knowledge
- Regulatory ambiguity
- Independent distributor misconduct
- Deficiencies in chain-of-custody evidence
- Unreliable whistleblower testimony
- Inaccurate financial loss calculations
In many investigations, the central issue is not whether a compliance failure occurred. The dispute often centers on whether executives knew the products were unauthorized or reasonably relied on certifications provided by suppliers.
The distinction between a regulatory violation and a federal felony can become a major issue throughout the case.
Hypothetical Case Study: Alleged Gray-Market Oncology Drug Distribution Scheme
A national pharmaceutical distribution company generated substantial profits by sourcing oncology biologics through a network of international intermediaries.
Federal investigators alleged that several products entered the United States outside approved distribution channels and that executives concealed their origins through layered transactions involving foreign entities.
Prosecutors claimed the company submitted reimbursement claims for products represented as FDA-authorized biologics while internal emails allegedly showed concerns about sourcing practices.
A grand jury investigation resulted in allegations of healthcare fraud, conspiracy, wire fraud, and false statements against multiple executives.
Eisner Gorin LLP develops a defense strategy focused on the government's ability to prove knowledge and intent.
The attorneys identify evidence showing the executives relied on certifications from suppliers, independent regulatory consultants, and quality-control personnel.
The team also challenges the government's interpretation of industry communications that prosecutors characterize as evidence of wrongdoing.
Further investigation reveals that several intermediaries altered documentation before products reached the company.
Internal compliance reviews demonstrate that executives repeatedly requested verification regarding product authenticity and regulatory status.
By challenging the government's theory of intent and presenting evidence of extensive due diligence, the case shifts away from allegations of deliberate fraud and toward a dispute over complex international pharmaceutical sourcing practices.
The investigation concluded with a civil regulatory resolution, avoiding criminal convictions and preserving the executives' ability to continue working in the healthcare industry.
What Penalties Can Result from a Conviction?
Federal biologics procurement fraud allegations can expose defendants to severe consequences. A conviction for these fraud charges can include:
- Lengthy federal prison sentences
- Significant criminal fines
- Restitution orders
- Asset forfeiture
- Exclusion from federal healthcare programs
- Corporate integrity agreements
- Professional licensing consequences
- Reputational harm affecting future business opportunities
Speak to a Federal Criminal Defense Lawyer
If you are under investigation for suspected violations involving 42 U.S.C. § 262, 18 U.S.C. § 1347, healthcare fraud, procurement fraud, counterfeit pharmaceuticals, unapproved biosimilars, or false claims, it is crucial to seek early legal assistance.
At Eisner Gorin LLP, our federal criminal defense lawyers assist healthcare executives, pharmaceutical firms, distributors, procurement officers, wholesalers, and healthcare organizations involved in serious federal investigations.
We perform independent investigations, scrutinize intricate supply-chain evidence, dispute accusations of criminal intent, and strive to safeguard our clients' freedom, professional licenses, businesses, and reputations.
If you receive a grand jury subpoena, target letter, search warrant, FDA inquiry, or an interview request, avoid speaking with federal investigators until you have consulted with experienced counsel.
Contact Eisner Gorin LLP today at (818) 781-1570 for a confidential consultation to discuss your case and begin building a strategic defense.